The case for & against
Bull & Bear analysis
Bearish
Alaunos Therapeutics Inc. (NASDAQ: TCRT) is a biotechnology company focused on developing innovative T-cell receptor (TCR) therapies to treat solid tumors, with a specific emphasis on addressing high-frequency driver mutations. Utilizing its proprietary Sleeping Beauty transposon technology, Alaunos aims to revolutionize cancer treatments through personalized medicine. Currently in a phase of strategic transition, the company is shifting from tumor-specific therapies to also incorporate broader applications such as oral medicines targeting obesity and metabolic diseases.
Bull says
- ↑Achieved first confirmed partial response with non-viral TCR therapy in a solid tumor
- ↑Q4 2022 operating cash burn fell 22% to $7.1M
- ↑Collaboration revenues surged from $0.4M to $2.9M in 2022
- ↑Expanded TCR library could double addressable solid tumor patient pool
- ↑High qualitative growth factor suggests strong expansion potential
- ↑Cash reserves of $37.4M provide runway for ongoing trials
Bear says
- ↓Earnings yield of -1.36 and elevated leverage signal weak return prospects
- ↓Q1 2023 operating cash burn rose to $9.4M from $7.8M in Q1 2022
- ↓Analysts maintain a “Sell” consensus with low target prices
- ↓Patient matching below 5% threatens enrollment and extends timelines
- ↓2023 cash burn forecast of $35–40M risks runway if data delays occur
- ↓Book-to-price metrics suggest potential overvaluation relative to assets
Earnings Call · Q1 2022 · Mgmt. Guidance
Updated 08-04-2026neutral
Transcript signals
Bull points
- We continue to expect to report initial data in the second half of the year at a major medical meeting, which we believe is the most credible forum to present clinical data.
- Overall, we believe this has the potential to augment TCR T cell therapy and deepen clinical responses targeting hotspot mutations expressed in solid tumors.
- We look forward to advancing this program towards an IND filing in the second half of 2023.
Bear points
- For the first quarter of 2022, we reported a net loss of approximately $9.8 million, or 5 cents net loss per share, compared to a net loss of approximately $21.6 million, or 10 cents net loss per share for the first quarter of 2021.
- Clearly, if you look at the burn in the first quarter and multiply it times four, that doesn't get you to that range. But with the additional dosing of patients throughout the year and additional hiring to increase manufacturing throughput, we do anticipate and reiterate that guidance of operating cash burn between $40 and $45 million here for 2022.
- As I mentioned on our last call, I have reduced our expected operating cash flow for 2022 to between $40 and $45 million, a significant reduction year over year.
Read full transcript analysis ›